Publication | Open Access
SGLT6 - A pharmacological target for the treatment of obesity?
18
Citations
16
References
2018
Year
NutritionGastrointestinal Peptide HormoneObesityMetabolic SyndromeMolecular NutritionPublic HealthAppetite ControlEnergy HomeostasisObesity ManagementHuman Ingestive BehaviorMetabolomicsEndocrinologyPharmacologySugar PreferenceActive TransporterPhysiologyDiabetesNutritional NeurosciencePharmacological TargetNeuroscienceMetabolismMedicineDrug Discovery
Despite increased knowledge of nutrient intake regulation and energy homeostasis, treatment options for obesity remain limited. Food reward consists of two branches: gustatory and post-ingestive nutritive information. Drosophila lacking dSLC5A11 (sodium/glucose cotransporter 6-SGLT6) prefer L-glucose over D-glucose independently of their state of satiety. Human SGLT6 is an active transporter of myo-inositol and D-glucose. We investigated expression of SGLT6 in human tissue and found a significant expression in the small intestine and brain. The preference between a metabolizable and a non-metabolizable sugar was tested in 3 mouse models with a selective and potent SGLT6 inhibitor. No influence on sugar preference was seen with SGLT6 inhibition. These studies suggest that SGLT6 does not play a significant role in nutrient sensing in mammals.
| Year | Citations | |
|---|---|---|
2015 | 11.6K | |
2002 | 6.2K | |
2009 | 4.8K | |
2011 | 583 | |
Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus Volker Vallon, Michael Rose, Maria Gerasimova, American Journal of Physiology-Renal Physiology Kidney WeightRenal InflammationInsulin SignalingGlomerular HyperfiltrationMetabolic Syndrome | 2012 | 365 |
2010 | 300 | |
2011 | 229 | |
2011 | 218 | |
2002 | 163 | |
2013 | 155 |
Page 1
Page 1